

Bilenker Joshua H.
Form 4
June 21, 2018

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Bilenker Joshua H.

2. Issuer Name and Ticker or Trading Symbol
Loxo Oncology, Inc. [LOXO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
C/O LOXO ONCOLOGY, INC., 281
TRESSER BOULEVARD, 9TH
FLOOR

3. Date of Earliest Transaction
(Month/Day/Year)
06/19/2018

Director 10% Owner
 Officer (give title below) Other (specify below)
President & CEO

(Street)
STAMFORD, CT 06901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)				Price
Common Stock	06/08/2018		G	V	5,000	D	\$ 0	127,707	D	
Common Stock	06/19/2018		M ⁽¹⁾		7,500	A	\$ 1.184	135,207	D	
Common Stock	06/19/2018		S ⁽¹⁾		2,336 ⁽²⁾	D	\$ 176.2016 ⁽³⁾	132,871	D	
Common Stock	06/19/2018		S ⁽¹⁾		3,427 ⁽²⁾	D	\$ 177.0556 ⁽⁴⁾	129,444	D	

Edgar Filing: Bilenker Joshua H. - Form 4

Common Stock	06/19/2018	S ⁽¹⁾	<u>1,737</u> ⁽²⁾	D	\$ <u>178.1172</u> ⁽⁵⁾	127,707	D	
Common Stock	06/19/2018	S	<u>8,232</u> ⁽²⁾	D	\$ <u>177.4359</u> ⁽⁶⁾	41,768 ⁽⁷⁾	I	By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17
Common Stock	06/19/2018	S	<u>8,763</u> ⁽²⁾	D	\$ <u>178.297</u> ⁽⁸⁾	33,005	I	By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17
Common Stock	06/19/2018	S	<u>3,902</u> ⁽²⁾	D	\$ <u>179.8333</u> ⁽⁹⁾	29,103	I	By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17
Common Stock	06/19/2018	S	103 ⁽²⁾	D	\$ <u>180.3368</u> ⁽¹⁰⁾	29,000	I	By Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17
	06/20/2018	M	28,000	A	\$ 1.184	155,707	D	

Edgar Filing: Bilenker Joshua H. - Form 4

Common Stock							
Common Stock	06/20/2018	M ⁽¹⁾	7,500	A	\$ 1.184	163,207	D
Common Stock	06/20/2018	S ⁽¹⁾	2,700 <u>(2)</u>	D	\$ 178.8052 <u>(11)</u>	160,507	D
Common Stock	06/20/2018	S ⁽¹⁾	4,370 <u>(2)</u>	D	\$ 179.3697 <u>(12)</u>	156,137	D
Common Stock	06/20/2018	S ⁽¹⁾	430 <u>(2)</u>	D	\$ 180.8965 <u>(13)</u>	155,707	D

Common Stock	06/20/2018	S	11,336 <u>(2)</u>	D	\$ 178.9437 <u>(14)</u>	17,664	I
--------------	------------	---	----------------------	---	-------------------------------	--------	---

By
Joshua H. Bilenker,
Trustee
for the
Joshua H. Bilenker
2017
GRAT
u/a DTD
06/16/17

Common Stock	06/20/2018	S	9,664 <u>(2)</u>	D	\$ 179.773 <u>(15)</u>	8,000	I
--------------	------------	---	---------------------	---	---------------------------	-------	---

By
Joshua H. Bilenker,
Trustee
for the
Joshua H. Bilenker
2017
GRAT
u/a DTD
06/16/17

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	------------------------------------	--	---

Edgar Filing: Bilenker Joshua H. - Form 4

- (4) Represents the weighted average sales price per share. The shares sold at prices ranging from \$176.64 to \$177.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (5) Represents the weighted average sales price per share. The shares sold at prices ranging from \$177.67 to \$178.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (6) Represents the weighted average sales price per share. The shares sold at prices ranging from \$177.00 to \$177.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (7) Joshua H. Bilenker, Trustee for the Joshua H. Bilenker 2017 GRAT u/a DTD 06/16/17 previously reported as held directly pursuant to Rule 16a-13.
- (8) Represents the weighted average sales price per share. The shares sold at prices ranging from \$178.03 to \$179.00 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (9) Represents the weighted average sales price per share. The shares sold at prices ranging from \$179.20 to \$180.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (10) Represents the weighted average sales price per share. The shares sold at prices ranging from \$180.23 to \$180.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (11) Represents the weighted average sales price per share. The shares sold at prices ranging from \$178.08 to \$179.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (12) Represents the weighted average sales price per share. The shares sold at prices ranging from \$179.09 to \$180.02 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (13) Represents the weighted average sales price per share. The shares sold at prices ranging from \$180.85 to \$180.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (14) Represents the weighted average sales price per share. The shares sold at prices ranging from \$178.50 to \$179.48 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (15) Represents the weighted average sales price per share. The shares sold at prices ranging from \$179.50 to \$180.04 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- (16) The options have fully vested and are immediately exercisable.
- (17) Option exercises that were previously reported by the Reporting Person were attributed to a single option grant in each prior Form 4 filed by the Reporting Person with the Securities and Exchange Commission. This Form 4 combines two option grants with identical terms and reports the respective option exercises in the aggregate on one row. The shares reported in this column as beneficially owned following the reported transaction represents the outstanding shares underlying both option grants.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.